Drug intelligence / Profile preview

VM-PAIN-004

Development stage: Unknown
Lead developer: VivaMed BioPharma
Modality: Small Molecules

Overview

VM-PAIN-004 is a small molecule drug candidate currently in Phase 3 clinical development by VivaMed BioPharma. It is specifically targeted toward the treatment of neuropathic pain and Complex Regional Pain Syndrome (CRPS), a chronic pain condition that typically affects a limb following injury or trauma. While the drug has reached late-stage clinical testing, the developer has not publicly disclosed its specific molecular mechanism of action or biological target. It represents a key asset in VivaMed's pain management pipeline, which also includes candidates for trigeminal neuralgia and postoperative pain.

Beyond the preview

Go deeper on VM-PAIN-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VM-PAIN-004.

Explore the full profile